Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROP3: Low-Dose Bevacizumab vs Laser for Type 1 ROP
NCT04634604Phase 3Terminated
- Sponsor
- Jaeb Center for Health Research
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of bevacizumab in retinopathy of prematurity (ROP), sponsored by Jaeb Center for Health Research. Started Apr 2022; status: terminated.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04634604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634604.